Dr. Michaela Arndt

Dear client,
For better user experience, you need modern browsers that are up-to-date. The version of your browser you are using is out of date; this poses a security risk. Please use another browser.
Thank you for your understanding.

Dr. Michaela Arndt, PhD


Michaela Arndt is co-founder and CEO of Heidelberg ImmunoTherapeutics since its inception in 2016. In this role, she is responsible for the strategic leadership and corporate development of the company. She brings in her strong scientific background in clinical translation and expertise in the development of immunotherapeutics. Before assuming her current position as CEO of Heidelberg ImmunoTherapeutics, her positions in academia as scientific co-leader of the ‘Antibody-based Immunotherapeutics Development Group’ at the National Center for Tumor Diseases Heidelberg (NCT) and founding group leader of the ‘Recombinant Therapeutic Antibody Group’ at Essen University Hospital focused on early preclinical development of antibody and antibody-derived therapeutics. After receiving her PhD at the German Cancer Research Center in Heidelberg she held a postdoctoral position at the National Cancer Institute (NCI) of the National Institute of Health (NIH)/United States from 2000 to 2003.